If Sanofi opts in to the other project, Regeneron will lead MUC16xCD3 bispecific development and marketing in the US. The companies will share development costs and profits.

Sanofi is to make a huge $2.18 billion investment in the collaboration with Regeneron, buying into the US firm's PD-1 inhibitor candidate, currently in phase I.

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in ... added to background maximal standard-of-care inhaled therapy in adults with uncontrolled COPD ...